Loading...
•
Sep 30, 2024
Boston Scientific Q3 2024 Earnings Report
Boston Scientific's financial performance for Q3 2024 showed strong growth, driven by its product pipeline and commercial execution.
Key Takeaways
Boston Scientific reported net sales of $4.209 billion, representing a 19.4% increase compared to the prior year period. The company's GAAP net income attributable to Boston Scientific common stockholders was $0.32 per share, and adjusted EPS was $0.63 per share.
Net sales increased by 19.4% on a reported basis, exceeding the company's guidance range.
GAAP net income attributable to Boston Scientific common stockholders was $0.32 per share, while adjusted EPS reached $0.63 per share.
MedSurg segment net sales grew by 10.3%, and Cardiovascular segment net sales grew by 25.0%.
The company received FDA approval for the navigation-enabled FARAWAVE™ NAV Ablation Catheter and FDA 510(k) clearance for the new FARAVIEW™ Software.
Boston Scientific
Boston Scientific
Boston Scientific Revenue by Segment
Boston Scientific Revenue by Geographic Location
Revenue by Segment
MedSurg Revenue
CapyFin.comCardiovascular Revenue
CapyFin.comRevenue by Geographic Location
Emerging Markets Revenue
CapyFin.com Forward Guidance
The company provided net sales growth and EPS estimates for the full year and fourth quarter of 2024.
Positive Outlook
- Net sales growth for the full year 2024 is estimated to be approximately 16.5% on a reported basis.
- Full year EPS is estimated in a range of $1.28 to $1.30 on a GAAP basis.
- Adjusted EPS for the full year is estimated to be $2.45 to $2.47.
- Net sales growth for the fourth quarter of 2024 is expected to be in the range of 16.5% to 18.5% on a reported basis.
- Fourth quarter EPS is projected to be $0.41 to $0.43 on a GAAP basis.
Challenges Ahead
- Full year organic net sales guidance excludes the impact of foreign currency fluctuations.
- Full year organic net sales guidance excludes net sales attributable to acquisitions and divestitures.
- Fourth quarter organic net sales guidance excludes the impact of foreign currency fluctuations.
- Fourth quarter organic net sales guidance excludes net sales attributable to acquisitions and divestitures.
- EPS and adjusted EPS estimates exclude certain charges (credits).
Revenue & Expenses
Visualization of income flow from segment revenue to net income